Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Quarterly Earnings Results

Phathom Pharmaceuticals (NASDAQ:PHAT) released its quarterly earnings results on Thursday. The company reported ($3.97) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.25) by ($2.72), Fidelity Earnings reports.

Shares of NASDAQ PHAT opened at $26.00 on Friday. The firm has a 50-day moving average of $34.80. Phathom Pharmaceuticals has a fifty-two week low of $18.51 and a fifty-two week high of $47.84.

PHAT has been the topic of several recent research reports. Evercore ISI initiated coverage on Phathom Pharmaceuticals in a research note on Wednesday, November 27th. They issued an “outperform” rating on the stock. Jefferies Financial Group initiated coverage on Phathom Pharmaceuticals in a report on Wednesday, November 27th. They issued a “buy” rating and a $32.00 price objective for the company. ValuEngine upgraded Phathom Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday. Goldman Sachs Group initiated coverage on Phathom Pharmaceuticals in a report on Wednesday, November 27th. They issued a “neutral” rating and a $32.00 price objective for the company. Finally, Needham & Company LLC initiated coverage on Phathom Pharmaceuticals in a report on Wednesday, November 27th. They issued a “buy” rating and a $40.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $34.67.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related diseases.

Featured Story: How does the Beige Book influence monetary policy?

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.